Objectives The efficiency of the Astree e-tongue and Taste Sensing system TS5000Z for the evaluation of the taste masking effect of hot melt extruded formulations was investigated in this study. Methods Hot melt extrusion (HME) processing was optimized using Randcastle single screw extruder (USA) to manufacture extrudates with desirable characteristics. Cationic model drug propranolol HCl (PRP) was processed with the anionic polymers -Eudragit L100® (L100) and Eudragit L100-55 (Acryl-EZE). In vitro taste masking efficiency of the two polymers was performed by using two different e-tongues (Astree e-tonge and TS5000Z). Key Findings Both e-tongues were able to detect the taste masking variations of the extrudates and were in good agreement with the in vivo results obtained from a panel of six healthy human volunteers (R2>0.84). However, each e-tongue sensor demonstrated different sensitivity suggesting a careful consideration of the experimental findings during melt extrusion is necessary for the development of taste masked formulations. Furthermore, FT-IR spectroscopy and NMR studies revealed possible drug polymer intermolecular interactions as the mechanism of successful taste masking. Conclusions HME can effectively be used to manufacture taste masked extruded formulations while both e-tongues demonstrated satisfactory taste analysis for the development of taste masked formulations. Objectives The efficiency of the Astree e-tongue and Taste Sensing system TS5000Z for the 3 evaluation of the taste masking effect of hot melt extruded formulations was investigated in 4 this study. 5
Masking the bitter taste of active pharmaceutical ingredients (APIs) is considered a major 31 challenge especially for the development of orally administered dosage forms in 32 pharmaceutical industry. [1, 2] Due to the unpleasant sensation bitter taste is always the least 33 desired and sometimes completely undesired option whereas sweet taste is pleasant for most 34 of the people regardless their age and origin. [3] In reality most of the APIs used in oral drug 35 products have a bitter taste which is not only undesirable but also frequently has a negative 36 influence on the palatability of the final dosage forms. For paediatric population 37 unpalatable/bitter taste is the most challenging as children are highly sensitive to taste and 38 actively refuse the unpalatable drugs. [4, 5] It is often impossible to block bitter taste receptors 39 (due to their increased numbers) from the drug without compromising the mechanism of its 40 action. [6, 7] The extent of taste masking of an API depends almost exclusively on the type of 41 formulation (solid or liquid). Being the first preference, commercial oral liquid dosage forms 42 contain artificial sweeteners (e.g saccharin and aspartame) and flavours to mask the tastes 43 which are often limited due to the regulatory requirements. Due to very poor effects of this 44 method and possibilities of toxic and allergic reactions, European Medicines Agency (EMA) 45 strongly recommends another way for taste masking instead of adding sweeteners or flavours. 46 [8] An ideal solution for this problem should involve the prevention of any contact of the 47 unpalatable APIs with the taste buds without the addition of taste additives. Such an ideal 48 formulation can be developed by applying an appropriate coating or encapsulation on the API 49 or via manufacturing solid dispersions [9, 10] in inert matrices (polymeric/ lipidic). The coated/ 50 encapsulated drug then can be dispersed in water. 51
In vivo taste masking evaluation studies are performed by healthy human volunteers 52 and involve taste assessments based on the individual scores.
[11] A well-established statistical 53 method is required to overcome errors and variability between volunteers within the limit of 54 threshold taste perceptions. According to the FDA guidelines studies on paediatric 55 formulations should not be performed on paediatric volunteers due to ethical conflicts. On the 56 other hand in order to design paediatric formulations mature volunteers should also be 57 prohibited due to large physiological differences of taste sensation. [7] Ethical doubts on 58 experiments in children and difficulties with interpretation of the results eventually indicate 59 the need to use alternative in vitro methods for taste evaluations. [4, 7] In the last few years, 60 electronic tongues (e-tongues) became popular for the evaluation of the in vitro taste 61 performance for repeatable analysis of pharmaceutical products. [12, 13] 
73
The aim of this novel study is the evaluations of the taste masking efficiency of hot 74 melt extruded formulations of bitter API (PRP) by using two different e-tongues (Astree e-75 tongue and TS-5000Z) simultaneously and studying the mechanism of the effective taste 76 masking via extrusion processing. 77
Materials and methods

78
Materials 79
Propranolol HCl (PRP) was purchased from Sigma Aldrich (London, UK). Eudragit L100 80 (L100) and Eudragit L100-55 (Acryl-EZE) was kindly donated by Evonik Pharma Polymers 81 (Darmstadt, Germany) and Colorcon ltd respectively. The HPLC solvents were of analytical 82 grade and purchased from Fisher Chemicals (UK). All materials were used as received. 83
Preparation of formulation blends and hot-melt extrusion (HME) processing 84 PRP formulations with L100 and Acryl-EZE to be extruded were mixed properly in 100g 85 batches for 10 min each. A Turbula (TF2, Basel) mixer was used to blend the powder 86 formulations (drug/polymers ratio used were 10:90 w/w). Extrusion of all PRP formulations 87 were performed using a Randcastle single-screw extruder (RCP 0625, USA) equipped with a 88 5 mm rod die using 100°C/113°C/155°C/155°C/155°C (Feeder to die) temperature profiles. 89
The screw speed maintained for all extrusion was 15rpm. The produced extrudates (strands) 90 was grinded by using a Ball Milling system (8 balls, 1.5 cm diameter) to obtain granules 91 (<500 µm). Grinding by ball milling was carried out with a rotational speed of 400 rpm for 5 92
min. 93
Particle morphology and size distribution 94 Scanning Electron Microscopy (SEM) was used to study the surface morphology of the 95 extrudates. Samples were mounted on an aluminum stage using adhesive carbon tape which 96 was then placed in a low humidity chamber prior to the analysis. Samples were also coated with gold-palladium, and microscopy was performed using Cambridge Instruments -S630 98 (Cambridge, UK) operating at an accelerating voltage of 5 kV. All samples were run singlet. 99
The particle size distribution of the micronized granules of all formulations was 100 measured by dry sieving. The method involved stacking of the sieves on top of each other 101 and then placing the test powder (50 g) on the top sieve. The nest of sieves was subjected to a 102 standardized period of agitation (20 min) and then the weight of the material retained on each 103 sieve was accurately determined to give the weigh percentage of powder in each sieve size 104 range. All samples were run triplicate. 
In vivo taste masking evaluation 115
In vivo taste masking evaluation of pure API, polymers and all active extruded formulations 116 was performed in accordance to the Code of Ethics of the World Medical Association 117 (Declaration of Helsinki). [19] Six (6) fixed at 120s. [19] All the data generated on Astree system were treated using 132 to evaluate the differences and similarities between various samples or groups of samples. 139
The samples are represented in a two-dimensional or three-dimensional space with reference 140 to the selected components (PC1 and PCn). The components are classified according to the 141 level of information they produce. Astree sensors were cleaned up with deionised water 142 between each sample measurement. 143
Sample preparation for Astree E-Tongue 144
In vitro taste masking evaluation was carried out with an Astree E-Tongue equipped with 7 145 different sensor sets. To be as close as panellists taste's conditions, each drug was diluted for 146 60s under magnetic stirring in 25 ml of deionised water to reach API concentration 147 corresponding to a final dose of 100 mg. Then solutions were filtered (as the particles can 148 damage the ASTREE sensors and thus alter the quality of results) with Buchner funnel fitted 149 with filter paper at 2.5µm pore size (Table 1) . Analysis for each API was done in triplicate. 150
In vitro taste masking evaluation: TS-5000Z sensing system 151
The assays were realized on TS-5000Z taste sensing system equipped with a BASIC sensor 152 set (for pharmaceutical analysis) which are suitable for basic APIs composed of 10 specific 153 sensors (AAE, CT0, CA0, C00, AE1, AC0, AN0, BT0, GL1 ) on a 48-positions autosampler 154 using 25 ml beakers. Each measurement cycle was consisted of measuring a reference 155 solution (Vr) followed by sample solution (Vs) and then the aftertaste (Vr) followed by a 156 cleaning procedure. The ''aftertaste'' was measured by determining the change in membrane 157 potential caused by the adsorption of the analyte to the lipid membrane. Sensor outputs for 158 both taste (also called relative value (R)) and ''aftertaste'' were then calculated in relation to 159 the initially determined sensor response to the reference solution (Vr). [1, 22] Acquisition times 160 were fixed at 120s with a BT0 negatively charged sensor. All the data generated on TS-161 5000Z system were treated using multidimensional statistics. Each solution was tested on TS-162 5000Z at least 4 times and triplicates were taken into account for the statistical treatment. concentration of the drug was 2mg/ml, the polymers were 18 mg/ml, and the drug/polymer 179 formulation was 20mg/ml (the overall drug content in the formulations was 10%) (n=3).
1 H 180 T 1 relaxation experiments were recorded for all samples using a standard inverse recovery 181 experiment. Recovery delays (τ) were investigated between 10 ms and 20 s. The relaxation 182 delay was set to be >5T 1. T 1 s were calculated from curve fitting and peak intensities which 183 were obtained from the spectra recorded for different recovery delays. Jeol, curve fitting 184 software was utilized during this process. 185
Statistical analysis 186
All data generated and collected during in vitro taste analysis by both the e-tongue and taste 187 sensing system TS-5000Z were treated by statistical methods. Results were expressed as raw 188 data in mV of the sample relative measurement to the reference. [6] It has been reported in previous studies that if the 215 difference of the solubility parameters between drug and polymer is less than 7MPa 1/2 , then 216 the polymer is likely to be miscible with the API to form an amorphous solid dispersions. [6] 217 As a result the cationic PRP may interact with the functional groups of the negatively charged 218 polymers to effectively mask bitter taste of the drug. 219 SEM was used to examine the surface morphology of the drug and extrudates. The 220 extrudates containing L100 and Acryl-EZE showed homogenous particles distribution on the 221 extrudates surface with PRP ( Fig. 1) indicating excellent HME processing of the extruded 222 materials to form solid dispersions. The particle size distribution depicted in Fig. 1 shows  223 particle sizes lower than 500 µm for most formulations ranging from 40 -400µm. A small 224 percentage can be seen at sizes <40µm as the milling process was optimized to reduce fines 225 in the final extruded batches. corresponding to Acryl-EZE and L100, respectively (Fig. 2) . A sharp melting peak was also 232 observed in the Acryl-EZE thermogram at 59. Previous studies [6] showed that the diffraction patterns of both PRP physical mixtures 247 exhibited crystalline peaks with reduced intensities corresponding to pure drug. The 248 diffractograms of the extruded formulations were characterized with the absence of drug 249 intensity peaks indicating amorphous or molecularly dispersed state. 250
In vivo taste masking 251
The masking efficiency of the developed granules was evaluated in vivo (approved by 252
University of Greenwich, UK ethics committee) with the assistance of six healthy human 253 volunteers (age 18 -25). The statistical data collected from the in vivo study for the pure 254 active substance and the extruded formulations are depicted in Fig. 1 . The data analysis 255 showed significant suppression (p< 0.05) of the bitter taste for the API. These results 256 demonstrate the influence of the polymeric carriers and importance of drug loading in the 257 final formulation. Both polymers showed effective taste masking capacity with descending 258 order L100> Acryl-EZE. Furthermore, the HME formulations presented excellent masking 259 effect for active concentrations (10%) of the API. This could be due to the possible drug 260 polymer interactions in the solid dispersions manufactured during extrusion process. In the 261 solid dispersions cationic active substance (PRP) may have interacted with the functional 262 group of the negatively charged polymers. These interactions facilitated a hydrogen bonding 263 interaction between the active amide group of API and carboxylic group of polymers and 264 consequently masked the bitter taste of the active. A similar study has also been reported 265 elsewhere.
[2] In Fig. 3 the sensory data obtained from the panelists interestingly showed that 266 the taste masking efficiency of L100 is not similar to that of Acryl-EZE for the API used. 267
This could be attributed to the pH dependant dissolution properties of Acryl-EZE (pH ≥ 5.5)F o r R e v i e w O n l y compared to that of L100 (pH ≥ 6) as the saliva represents a basic pH (~7.4) in healthy 269 individuals. However, the sensory scores of the API in different formulations are within the 270 range (below 2) which has been demonstrated as optimum by in vitro evaluations. [1, 11] 271
In vitro taste evaluations (Astree e-tongue) 272
Astree e-tongue was used for in vitro taste analysis of the drug and active formulations. 273
Principal Component Analysis (PCA) associated to complementary data processing was used. 274 [20] Based on the statistical analysis taste maps were constructed in order to determine the 275 distances between active and polymer solutions. Actually the distance between each active 276 formulation and its corresponding placebo is indicative of how close or how far the taste of 277 the two samples is. The interpretation of the taste maps suggests that the shorter the distance 278 (Euclidean distance) between active and placebo (polymer), the better the taste masking of 279 the active ingredient. Thus the distance between any drug polymer pairs in the taste maps is 280 indicative of the taste masking efficiency of the extruded polymer formulations from which 281 the estimated Discrimination Index (DI in %) can be determined for each solution. This 282 indicator (DI) takes into account the average difference between the pairs (i.e drug and active 283 formulation or polymer and active formulation) to compare the dispersion or taste masking 284 effect. It is assumed that the higher the DI values (maximum 100%), the longer the distance 285 between groups and the lower the masking effects. 286
In Fig. 4a , the taste map shows significant discrimination between placebo and active 287 solutions with PRP. Liquid sensors were able to detect the presence of the drug in the 288 extruded formulations. Considering the pure drug in deionized water the extrudates with 289 L100 (10% drug loading w/w) shows a better taste improvement compared to that of Acryl-290 EZE (Fig. 4a) . The distance between the placebo and the active formulations indicates the 291 efficiency of the taste masking of the active by both polymers. The observed distance 292 proximity between extrudates of PRP and placebo is noticeable (for an example, 19% taste 293 improvements of PRP with L100). This trend is likely to be linked with a pH influence of 294 Acryl-EZE in deionized water (pH ~5.5) which leads to a higher separation of placebo from 295 the active formulations by dissolving faster than L100 (pH > 6.0). From the PCA graphs it 296 can be seen that the placebo, the API, and the extrudates are discriminated which means 297 significant taste differences. 298
Based on the Astree e-tongue experimental results it was also possible to design the 299 DI graphs for the drug -polymer combinations. In Fig. 4b , it can be seen that the distance 300 between active and placebo formulations with Acryl-EZE (DI 62%) is higher than that of 301 formulations. In addition, the discrimination index (DI, %) was determined for each solution. 337
Initial trials showed that the BT0 sensor of TS-5000Z system responded to the DPD and PRP 338 at the each concentration ranging from 0.03, 0.1, 0.3 and 1 mM. Therefore, BT0 sensor can 339 be useful for detecting bitterness of the API in the concentration ranging from 0.03 to 1 mM. 340
In contrast with the Astree e-tongue, in INSENT TS-5000Z system, the lower DI 341 values the longer the distance in taste responses between the pairs (drug and formulations) 342 and thus a higher discrimination, which means greater masking effect. The DI (%) values can 343 help to assess the significance of difference between the formulations. In Fig. 5a the bitter 344 taste suppression of PRP in the L100 extrudates is quite significant even after 30 min as the 345 DI index (%) is only about 60% while after 1 min DI is 40% (DI index (%) close to 0% 346 indicates no taste). In contrast the PRP/ Acryl-EZE extrudates (Fig. 5b) did not show taste 347 suppression similar to the L100 polymer but still the DI index (%) estimated by the BT0 348 sensor around 98% after 30 min and 85% in 1 min, respectively was considered effective (but 349 less than L100). 350
The normalized taste graphs showed significant discrimination between all active 351 formulations and active ingredient solutions (Fig. 5a-b) suggesting lower taste masking 352 efficiency of Acryl-EZE for the API compared to the taste suppression of L100. Sensory correlated models were built to evaluate the correlation with sensory scores. 361
The correlation model was considered as valid and fitted with panel perception (Fig 5c) and 362 complemented the sensory findings from the panelists' scores to conclude the statement that 363 L100 has better taste masking efficiency than Acryl-EZE. The TS-5000Z taste sensing 364 system demonstrated different sensitivity to each sample with high correlation (R 2 =0.94) to 365 the taste scores, suggesting that the sensor responds selectively according to bitterness 366 intensity by providing quantitative information. 367
The BT0 sensor was also used to determine the taste of pure polymers. Interestingly 368 as shown in Fig. 5d it was not possible to detect any taste for both L100 and Acryl-EZE. 369 FT-IR has been used to study interactions in drug/polymer dispersions by providing valuable 374 information regarding the oppositely charged ionic drug/polymer interactions at molecular 375 level.
[23] By showing the appearance of additional bands, alterations in wavenumber position 376 or broadening of functional groups compared to the spectra of the pure drug and polymer the 377 FTIR spectra gives an indication of drug/polymer interactions. The FTIR spectra for the 378 extruded formulations are shown in Fig.6 . 379
The characteristic bands of CO-vibrations of the carboxylic acid groups in L100 and 380
Acryl-EZE are shown at ~1705 cm -1 and of the esterified carboxylic groups at ~1735 cm -1
. 381
The FTIR spectra of the PRP extrudates in comparison with the pure materials are depicted in 382 Fig. 6 , which showed a new absorption band at ~1560 and ~1555 cm -1 for PRP/ L100 and 383 PRP/ Acryl-EZE, respectively. This is considered to be the result of the presence of amine 384 group alongside the carboxyl group in the solid dispersions.
[24] During the FTIR process the 385 resonance is possible between the two CO-bands within COO-groups. As a result, the 386 characteristic CO-absorption is replaced by the band of auto-symmetrical vibrations of the 387 COO-group in the 1555-1560 cm -1 region of the FTIR spectra [24, 25] which belongs to the 388 polymer (L100 or Acryl-EZE). This type of spectra changes provides strong evidence of 389 strong interactions between the anionic methacrylate polymers (-COO) and the cationic PRP 390 solutions. [26, 27] Previous studies showed that NMR analysis carried in DMSO successfully 397 revealed possible drug/polymer interactions in molecular level. Initially solid state NMR was 398 conducted in order to elucidate possible drug/polymer interactions; however the low drug 399 loading in our formulations didn't accord NMR a meaningful interpretation. SEM images of PRP/polymer extrudates and particle size distribution.
Fig. 2
DSC thermal transitions of (i) PRP and polymers pure, (ii) PRP/polymer extruded formulations.
Fig. 3
Sensory scores of all formulations by panelist (n=6).
Fig. 4a
Signal comparison between active and placebo formulations with L100 and Acryl-EZE and PRP (dissolution for 60s).
Fig. 4b
Distance and discrimination comparison between signal of PRP pure and their formulations on Astree e-tongue (after 60s dissolution).
Fig. 4c
Sensory correlation model based on PLS with Astree e-tongue
Fig. 5a
Normalised DI (%) of all drug/L100 formulations in four different time scale.
Fig. 5b
Normalised DI (%) of all drug/ Acryl-EZE formulations in four different time scale.
Fig. 5c
Relationship between results of taste sensors and human taste scores for similar tastes. The standard deviations on the x-and y-axes are the difference between the panelists' scores and measurement error (n = 6), respectively.
Fig. 5d
Sensor output of the two polymers, Acryl-EZE and L100. Maximum concentrations of polymers were set at 60 times the maximum API conc.
(approx. 0.5 mg/mL x 60 = 30 mg/mL).
Fig. 6
FT-IR spectra of PRP extruded formulations. 
